Thyroglobulin measurement is the most powerful outcome predictor in differentiated thyroid cancer: a decision tree analysis in a European multicenter series

Author:

Giovanella Luca12,Milan Lisa3,Roll Wolfgang4,Weber Manuel5,Schenke Simone6,Kreissl Michael6,Vrachimis Alexis7,Pabst Kim5,Murat Tuncel8,Petranović Ovčariček Petra9,Campenni Alfredo10,Görges Rainer5,Ceriani Luca3

Affiliation:

1. Nuclear Medicine , Gruppo Ospedaliero Moncucco , Lugano , Switzerland

2. Nuclear Medicine , University Hospital Zürich , Zürich , Switzerland

3. Nuclear Medicine , Ente Ospedaliero Cantonale , Bellinzona , Switzerland

4. Nuclear Medicine , University Hospital Münster , Münster , Germany

5. Nuclear Medicine , 39081 University Hospital Essen , Essen , Germany

6. Nuclear Medicine , University Hospital Magdeburg , Magdeburg , Germany

7. Nuclear Medicine , German Oncology Center , Limassol , Cyprus

8. Nuclear Medicine , Hacettepe University , Ankara , Türkiye

9. Oncology and Nuclear Medicine , University Hospital Center “Sestre milosrdnice” , Zagreb , Croatia

10. Nuclear Medicine , University Hospital Messina , Messina , Italy

Abstract

Abstract Objectives An accurate prognostic assessment is pivotal to adequately inform and individualize follow-up and management of patients with differentiated thyroid cancer (DTC). We aimed to develop a predictive model for recurrent disease in DTC patients treated by surgery and 131I by adopting a decision tree model. Methods Age, sex, histology, T stage, N stage, risk classes, remnant estimation, thyroid-stimulating hormone (TSH), thyroglobulin (Tg), administered 131I activities and post-therapy whole body scintigraphy (PT-WBS) were identified as potential predictors and put into regression algorithm (conditional inference tree, c-tree) to develop a risk stratification model for predicting persistent/recurrent disease over time. Results The PT-WBS pattern identified a partition of the population into two subgroups (PT-WBS positive or negative for distant metastases). Patients with distant metastases exhibited lower disease-free survival (either structural, DFS-SD, and biochemical, DFS-BD, disease) compared to those without metastases. Meanwhile, the latter were further stratified into three risk subgroups based on their Tg values. Notably, Tg values >63.1 ng/mL predicted a shorter survival time, with increased DFS-SD for Tg values <63.1 and <8.9 ng/mL, respectively. A comparable model was generated for biochemical disease (BD), albeit different DFS were predicted by slightly different Tg cutoff values (41.2 and 8.8 ng/mL) compared to DFS-SD. Conclusions We developed a simple, accurate and reproducible decision tree model able to provide reliable information on the probability of structurally and/or biochemically persistent/relapsed DTC after a TTA. In turn, the provided information is highly relevant to refine the initial risk stratification, identify patients at higher risk of reduced structural and biochemical DFS, and modulate additional therapies and the relative follow-up.

Publisher

Walter de Gruyter GmbH

Reference18 articles.

1. Brassard, M, Borget, I, Edet-Sanson, A, Giraudet, AL, Mundler, O, Toubeau, M, et al.. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 2011;96:1352–9. https://doi.org/10.1210/jc.2010-2708.

2. Haugen, BR, Alexander, EK, Bible, KC, Doherty, GM, Mandel, SJ, Nikiforov, YE, et al.. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2015;26:1–33. https://doi.org/10.1089/thy.2015.0020.

3. Tuttle, RM, Tala, H, Shah, J, Leboeuf, R, Ghossein, R, Gonen, M, et al.. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system. Thyroid 2010;20:1341–9. https://doi.org/10.1089/thy.2010.0178.

4. Giovanella, L. Circulating biomarkers for the detection of tumor recurrence in the postsurgical follow-up of differentiated thyroid carcinoma. Curr Opin Oncol 2020;32:7–12. https://doi.org/10.1097/cco.0000000000000588.

5. Giovanella, L, D’Aurizio, F, Algeciras-Schimnich, A, Görges, R, Petra Petranovic Ovcaricek, P, Tuttle, RM, et al.. Thyroglobulin and thyroglobulin antibody: an updated clinical and laboratory expert consensus. Eur J Endocrinol 2023;189:R11–27. https://doi.org/10.1093/ejendo/lvad109.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3